Lower body mass index (BMI) is consistently associated with reduced type II diabetes risk, among people with varied family history, genetic risk factors and weight, according to a new study published this week in PLOS Medicine by Manuel Rivas of Stanford University, and colleagues.
Weight-loss interventions have shown demonstratable benefit for reducing the risk of type II diabetes in high-risk and pre-diabetic individuals but have not been well-studied in people at lower risk of diabetes. In the new study, researchers studied the association between BMI, diabetes family history and genetic risk factors affecting type II diabetes or BMI. They used data on 287,394 unrelated individuals of British ancestry recruited to participate in the UK Biobank from 2006 to 2010 when between the ages of 40 and 69.
Nearly 5% of the participants had a diagnosis of type II diabetes and diabetes prevalence was confirmed to be associated with higher BMI, a family history of type II disease and genetic risk factors. Moreover, a 1 kg/m2 BMI reduction was associated with a 1.37 fold reduction (95% CI 1.12-1.68) in type II diabetes among non-overweight individuals with a BMI of less than 25 and no family history of diabetes, similar to the effect of BMI reduction in obese individuals with a family history (1.21, 95% CI 1.13-1.29)
"These findings suggest that all individuals can substantially reduce their type II diabetes risk through weight loss," the authors say. However they also caution that the results must be taken with a grain of salt since they didn't study actual weight loss interventions. Although the new analysis "can determine that lower lifetime BMI is protective against diabetes, that does not necessarily imply weight loss later in life, after carrying excess weight for decades, would have the same result," they say.
This research has been conducted using the UK Biobank Resource under Application Number 24983, "Generating effective therapeutic hypotheses from genomic and hospital linkage data" (http://www.
I have read the journal's policy and the authors of this manuscript have the following competing interests: M.I.M has served on advisory panels for Pfizer, NovoNordisk, Zoe Global; received honoraria from Merck, Pfizer, NovoNordisk and Eli Lilly; has stock options in Zoe Global; and has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, Takeda. As of June 2019, M.I.M is an employee of Genentech and a holder of stock in Roche.
Wainberg M, Mahajan A, Kundaje A, McCarthy MI, Ingelsson E, Sinnott-Armstrong N, et al. (2019) Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study. PLoS Med 16(12): e1002982. https:/
Image Credit: HansMartinPaul, Pixabay
Department of Computer Science, Stanford University, Stanford, California, United States of America
Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, United Kingdom
Department of Genetics, Stanford University, Stanford, California, United States of America
NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom
Molecular Epidemiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Science for Life Laboratory, Uppsala University, Uppsala, Sweden
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America
Stanford Cardiovascular Institute, Stanford University, Stanford, California, United States of America
Department of Biomedical Data Science, Stanford University, Stanford, California, United States of America
In your coverage please use this URL to provide access to the freely available paper: http://journals.